Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib in DLBCL patients receiving R-CHOP
NCT06569485Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trilaciclib in myelosuppression, sponsored by Sun Yat-sen University. Started May 2024; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT06569485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569485.